396 related articles for article (PubMed ID: 29431860)
1. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
2. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
Imhof A; Walter RB; Schaffner A
Clin Infect Dis; 2003 Apr; 36(8):943-51. PubMed ID: 12684904
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
4. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
6. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.
Falagas ME; Karageorgopoulos DE; Tansarli GS
PLoS One; 2013; 8(10):e77075. PubMed ID: 24204739
[TBL] [Abstract][Full Text] [Related]
7. Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies.
Schulenburg A; Sperr W; Rabitsch W; Knöbl P; Thalhammer F
Leuk Lymphoma; 2005 Aug; 46(8):1163-7. PubMed ID: 16085557
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC.
Uehara RP; Sá VH; Koshimura ET; Prudente FV; Tucunduva LT; Gonçalves MS; Samano ES; del Giglio A
Sao Paulo Med J; 2005 Sep; 123(5):219-22. PubMed ID: 16358096
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the safety and cost-effectiveness of nebulized liposomal amphotericin B and amphotericin B deoxycholate for antifungal prophylaxis after lung transplantation.
Umemura K; Katada Y; Nakagawa S; Hira D; Yutaka Y; Tanaka S; Ohsumi A; Nakajima D; Date H; Nagao M; Terada T
J Infect Chemother; 2024 Aug; 30(8):741-745. PubMed ID: 38354908
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections.
Leenders AC; Daenen S; Jansen RL; Hop WC; Lowenberg B; Wijermans PW; Cornelissen J; Herbrecht R; van der Lelie H; Hoogsteden HC; Verbrugh HA; de Marie S
Br J Haematol; 1998 Oct; 103(1):205-12. PubMed ID: 9792309
[TBL] [Abstract][Full Text] [Related]
11. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
12. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
13. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
14. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
15. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
16. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
Altmannsberger P; Holler E; Andreesen R; Krause SW
J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868
[No Abstract] [Full Text] [Related]
18. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.
Eriksson U; Seifert B; Schaffner A
BMJ; 2001 Mar; 322(7286):579-82. PubMed ID: 11238151
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
20. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
